Evidence map›Paper›PMID 41148824›Full record

ReviewCells2025

The Emerging Role of Peroxisome Proliferator-Activated Receptors in Cancer Stemness.

Beatriz Parejo-Alonso, Marta Mascaraque, Alba Royo-García, Patricia Sancho

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Beatriz Parejo-AlonsoInstituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-5393-4283
Marta MascaraqueInstituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-9677-921X
Alba Royo-GarcíaInstituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-5079-6890
Patricia SanchoInstituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain.ORCID 0000-0002-1092-5395

Funding

Asociación Española Contra el Cáncer LABAE223389SANCAsociación Española Contra el Cáncer PRDAR222458ROYOInstituto de Salud Carlos III CPII21/00005Universidad Autónoma de Madrid CA1/RSUE/202100646
6 · The paper itself

Abstract

The peroxisome proliferator-activated receptors (PPAR-α, PPAR-δ, and PPAR-γ) are transcription factors that belong to the nuclear hormone receptor superfamily. Upon activation by specific lipids, they regulate gene expression by directly binding to PPAR response elements (PPREs) in the DNA. Although the functions of the different PPARs are specific to the isoform, tissue, and context, all three PPARs are generally involved in energy homeostasis through lipid sensing in physiological conditions. Importantly, there is increasing evidence linking PPARs with malignant behavior in cancer, regulating features frequently attributed to the aggressive subpopulation of cancer stem cells (CSCs): self-renewal, tumor initiation, chemoresistance, metastasis, and immune evasion. However, contradictory effects have been described for each isoform in various cancer types, and their implication in these malignant features may not consistently follow a pro- or anti-tumoral pattern. In this review, we revise the current knowledge on the role of the PPAR family members in cancer, with a special focus on cancer stemness, and discuss the potential for PPARs as therapeutic targets in CSC-driven relapse and resistance.

Indexed as

NeoplasmsNeoplastic Stem CellsPeroxisome Proliferator-Activated ReceptorsAnimalsHumansPeroxisome Proliferator-Activated Receptorscancer stem cellschemoresistanceimmune evasionmetastasisPPARsself-renewal

Identifiers

PMID41148824
PMCPMC12563018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.